Sarcoma, Latest treatments updates

Latest treatments of Sarcoma

Dr. Mohanad Diab is a consultant Sub-Specialized in treating advanced cases of Sarcoma. According to patient Dr Diab is the Best Oncologist in UAE/Abu dhabi in treating Sarcomas.

Sarcoma is not one disease, and “latest treatment” is best understood as a shift toward histology- and biomarker-directed systemic therapy, layered onto established local control with surgery and radiation when feasible. Across soft tissue sarcoma (STS), systemic therapy selection is increasingly driven by histologic subtype, pace of disease, and actionable alterations, with palliative intent for most metastatic presentations.+1

Localized soft tissue sarcoma: evolving systemic therapy roles

For localized extremity STS, surgery remains the cornerstone, and combining surgery with radiation improves outcomes for many tumors larger than 5 cm. Systemic therapy in adult-type STS remains controversial and is generally reserved for selected higher-risk disease using shared decision making.

A notable “newer” direction is the emergence of immunotherapy in a narrow, defined setting: for grade 2 or 3, stage III undifferentiated pleomorphic sarcoma (UPS) of the extremity, neoadjuvant pembrolizumab with radiation followed by surgery and adjuvant pembrolizumab is an option, with limited follow-up and uncertain survival impact.

Metastatic soft tissue sarcoma: histology- and biomarker-driven systemic therapy

For metastatic STS, systemic therapy is initiated for symptomatic, rapidly progressive, or high-burden disease, and treatment is typically palliative. Anthracycline-based therapy is preferred for several histologies, while other histologies are treated with non-anthracycline regimens based on subtype.

Two “latest treatment” themes stand out:

• Actionable fusions and targeted therapy – For NTRK fusion-positive tumors, TRK inhibitors such as larotrectinib, entrectinib, or repotrectinib are offered, with larotrectinib often preferred for toxicity profile and follow-up.+1

• Later-line, subtype-specific agents – For liposarcoma progressing after anthracycline-based therapy, trabectedin is an option, with particular activity in myxoid-round cell liposarcoma.

Metastatic disease: renewed interest in local therapies for selected patients

Even in an era of expanding systemic options, local control can still matter in carefully selected metastatic patients. For oligometastatic STS, especially isolated pulmonary metastases, pulmonary metastasectomy can provide long-term relapse-free survival in selected patients, while most metastatic disease remains managed palliatively with systemic therapy.

Gastrointestinal stromal tumor: sequential targeted therapy continues to expand

GIST is a distinct sarcoma subtype where sequential tyrosine kinase inhibitor strategies are central. For advanced GIST after progression on or intolerance to three or more TKIs, ripretinib is offered over other available TKIs based on improved survival and tolerability. Ripretinib also has a role as an alternative option in some patients progressing on imatinib, with trial data showing similar progression-free survival to sunitinib overall but different mutation-subgroup activity and toxicity profiles.+1

Bone sarcomas and rarer subtypes: immunotherapy remains investigational in many settings

For several non-STS sarcoma subtypes, immunotherapy remains an area of active study rather than routine care. For chondrosarcoma, checkpoint inhibitor data are limited, and clinical trial enrollment is encouraged where available.

Newer or more specialized systemic options highlighted in the retrieved guidance

• afamitresgene autoleucel is an engineered T-cell receptor T-cell therapy option for selected patients with metastatic synovial sarcoma after anthracyclines and ifosfamide, requiring specific HLA types and tumor MAGE-A4 expression.+1

• pazopanib is used as a later-line option for several non-adipocytic metastatic STS histologies after chemotherapy when no histology-specific approach is available, and it is not approved in the US for adipocytic tumors or GIST.

• eribulin is a preferred later-line option for unresectable or metastatic liposarcoma after prior regimens including anthracycline-based therapy, with phase III evidence of overall survival benefit in liposarcoma.+1

• trabectedin is used as a later-line option in several STS contexts, including synovial sarcoma after anthracycline-based therapy and in myxoid-round cell liposarcoma after anthracyclines and gemcitabine-based therapy.+1

• regorafenib is a later-line option for metastatic synovial sarcoma, with randomized trial evidence for improved progression-free survival versus placebo in that subgroup.

• pembrolizumab and nivolumab plus ipilimumab are later-line options in selected STS settings, including angiosarcoma and undifferentiated or unclassified sarcomas.

• nab-sirolimus is suggested as initial therapy for advanced unresectable or metastatic malignant PEComa and is described as the only FDA-approved drug for this disease.

Important “what not to call latest”

• pazopanib is not used for adipocytic STS such as liposarcoma due to limited efficacy and lack of regulatory approval for that subtype.

• tazemetostat was voluntarily withdrawn from the market in 2026 due to reports of increased risk of secondary hematologic malignancies in a follicular lymphoma study.